News

Patented method developed in the laboratory of Dr Sandro Ataide promises to accelerate the potential of genetic engineering already shown by CRISPR gene-editing technology.

Researchers have developed a solution to retain the naïve state of cells in adoptive T-cell therapy, allowing them to be even better disease fighters when they are infused back into a patient.

Researchers have found promising evidence that brigatinib, a small molecule treatment approved for the treatment of lung cancer, helps to shrink the tumors of patients with NF2-related schwannomatosis.

Researchers at Purdue University’s College of Science have developed a patent-pending compound called HSN748 to treat drug-resistant acute myeloid leukemia (AML).

Scripps Research scientists found that a “one-two punch” of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, including Hodgkin lymphoma.

Scientists at the Brain Tumour Research Centre of Excellence at the University of Plymouth are conducting a clinical trial to see whether using anti-retroviral medications, Ritonavir and Lopinavir, could help people with Neurofibromatosis 2 (NF2).

When low doses of cancer drugs are administered continuously near malignant brain tumors using so-called iontronic technology, cancer cell growth drastically decreases.

Cancer patients develop fewer protective antibodies to SARS-CoV-2 than the general population, especially after a single vaccine dose, reports a new study.

Researchers at the Johns Hopkins Kimmel Cancer Center’s Sol Goldman Pancreatic Cancer Research Center have developed a 3D genomic profiling technique to identify small precancerous lesions in the pancreas.

University of Oxford researchers have leveraged the power of artificial intelligence (AI) to develop personalised cancer treatments which could be more effective at preventing patient relapse.